Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01794364 · ClinicalTrials.gov registry record · Phase 1

Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects

A Phase 1 study of Healthy, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
8
Enrollment target
1
Study location

NCT01794364 is a Phase 1 study of Healthy that has completed, run by Pfizer. The registered enrollment target is 8 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01794364, a Phase 1 study of Healthy, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of PF-06291874 in healthy volunteers.

Conditions Studied

Interventions

  • OTHER placebo
  • DRUG PF-06291874

Study Locations (1)

Connecticut

  • Pfizer Investigational Site - New Haven

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2013-01
Est. Completion 2013-03
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT01794364

The ClinicalTrials.gov registry entry for NCT01794364 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (99% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT01794364 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT01794364 about?

NCT01794364 is a clinical study titled "Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects". The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of PF-06291874 in healthy volunteers.

What is the current status of trial NCT01794364?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2013-01. Estimated completion is 2013-03.

What conditions does trial NCT01794364 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT01794364?

The interventions under investigation include: placebo (OTHER), PF-06291874 (DRUG).

Who is sponsoring clinical trial NCT01794364?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01794364 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.